Exocrine secretion of epidermal growth factor by the rat prostate: effect of adrenergic agents, cholinergic agents, and vasoactive intestinal peptide.

Jacobs SC, Story MT

The Prostate1 Jan 1988Cited by 25 (Europe PMC)

PMID3262216DOI10.1002/pros.2990130109PepBankPUB-03262216

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, VIP did not stimulate epidermal growth factor secretion into prostatic fluid.
In plain wordsIn rats, VIP did not raise the secretion of epidermal growth factor from the prostate.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeEGF secretion into prostatic fluid after VIP
Study
ratn: not reported in source
Rat prostatic urethra perfusion in vivo
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Vasoactive intestinal peptide (VIP) did not stimulate EGF secretion
1 context sentence(design, population, supporting numbers)
Summary · context
Perfusion of the rat prostatic urethra in vivo provided a means of collecting the rat prostatic secretory product.
Report a problemFND-0326221601
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, VIP did not augment pilocarpine-stimulated EGF secretion in prostatic fluid.
In plain wordsIn rats, adding VIP did not increase prostate EGF secretion beyond what pilocarpine alone caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeEGF secretion with VIP plus pilocarpine
Study
ratn: not reported in source
Rat prostatic urethra perfusion in vivo
Comparator
Pilocarpine alone
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
nor did it augment either pilocarpine or phenylephrine-stimulated secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
Perfusion of the rat prostatic urethra in vivo provided a means of collecting the rat prostatic secretory product.
Report a problemFND-0326221602
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, VIP did not augment phenylephrine-stimulated EGF secretion in prostatic fluid.
In plain wordsIn rats, adding VIP did not increase prostate EGF secretion beyond what phenylephrine alone caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeEGF secretion with VIP plus phenylephrine
Study
ratn: not reported in source
Rat prostatic urethra perfusion in vivo
Comparator
Phenylephrine alone
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
nor did it augment either pilocarpine or phenylephrine-stimulated secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
Perfusion of the rat prostatic urethra in vivo provided a means of collecting the rat prostatic secretory product.
Report a problemFND-0326221603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.